Nektar Therapeutics | NKTR - Equity Capital And Reserves


Nektar Therapeutics reported $89.83M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
ALKERMES USD 1.75B 67.76M Mar/2026
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
Amgen USD 9.19B 532M Mar/2026
Baxter International USD 6.04B 86M Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Cara Therapeutics USD 20.95M 6.92M Dec/2025
Cipla INR 344.32B 15.13B Mar/2026
Dr.Reddys Laboratories INR 378.92B 3.16B Mar/2026
Eisai JPY 898.99B 9.36B Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
Exelixis USD 1.94B 225.57M Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Grifols EUR 6.21B 133.12M Dec/2025
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Ironwood Pharmaceuticals USD -217.14M 44.69M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
MacroGenics USD 21.2M 34.39M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Takeda JPY 7.77T 129.5B Mar/2026
Teva Pharmaceutical Industries USD 8.23B 314M Mar/2026
Xencor USD 515.63M 119.95M Mar/2026